Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AKT1 | P31749 | 5/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.39 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.39 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.39 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.39 |
| ▸ | CDK2 | P24941 | 1/20 | 0.38 |
| ▸ | CA1 | P00915 | 1/20 | 0.37 |
| ▸ | CA9 | Q16790 | 1/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
| ▸ | SMYD3 | Q9H7B4 | 1/20 | 0.36 |
| ▸ | TSHR | P16473 | 2/20 | 0.36 |
| ▸ | NAMPT | P43490 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4900162 | 1.00 | AKT1 (0.41) | AKT1ALDH1A1LMNAMAPK1HDAC3 | |
| SCHEMBL4781246 | 0.97 | AKT1 (0.41) | AKT1ALDH1A1LMNAMAPK1HDAC3 | |
| SCHEMBL4891405 | 0.97 | AKT1 (0.41) | AKT1ALDH1A1LMNAMAPK1HDAC3 | |
| SCHEMBL4896077 | 0.97 | AKT1 (0.41) | AKT1ALDH1A1LMNAMAPK1HDAC3 | |
| SCHEMBL4901998 | 0.93 | AKT1 (0.41) | AKT1ALDH1A1LMNAMAPK1HDAC3 | |
| SCHEMBL4904361 | 0.93 | AKT1 (0.41) | AKT1ALDH1A1LMNAMAPK1HDAC3 | |
| SCHEMBL4899055 | 0.93 | GAA (0.41) | AKT1ALDH1A1HDAC3HDAC1HDAC2 | |
| SCHEMBL4901986 | 0.93 | ALDH1A1 (0.42) | AKT1ALDH1A1CDK2NAMPT | |
| SCHEMBL4903498 | 0.93 | ALDH1A1 (0.42) | AKT1ALDH1A1CDK2NAMPT | |
| SCHEMBL4898951 | 0.90 | AKT1 (0.41) | AKT1ALDH1A1HDAC3HDAC1HDAC2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080242694-A1 | Amino-substituted heterocycles, compositions thereof, and methods of treatment therewith | D SIDOCKY NEIL R | 2008-10-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080242694-A1 | Amino-substituted heterocycles, compositions thereof, and methods of treatment therewith | JAK2, CHEK2, MTOR | AKT1 26/4885ALDH1A1 1752/4885LMNA 1795/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.